046sek
-13,3 %
Date:2025-06-05Time:18:00:00Latest report:Q1-2025List:SpotlightTicker:PHAL
Market Cap:25 msekEnterprise Value:27 msekNet Sales:- msekEarnings:-4,08 msekEmployees:0ISIN:SE0003359710

Ratios

10-year key figure history for PharmaLundensis turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for PharmaLundensis with index and moving average MA50 and MA200.

Stockprice:0,46
MA50:0,63
MA200:0,64
Price/MA200:-27,9 %
RSI (14):42,4
Price/MA50:-26,9 %

Description

PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.

Biotechnology